邁克生物(300463.SZ):在供應鏈穩定的情況下,生免流水線本年裝機目標保持不變
格隆匯8月3日丨有投資者向邁克生物(300463.SZ)提問:對於自主的免疫生化產線流水線在營收端的帶動,公司預計什麼時候會有較為明顯的體現?
邁克生物回覆:在供應鏈穩定的情況下,生免流水線本年裝機目標保持不變,即不低於200條,另外血球流水線目標不低於200條。公司目前流水線主要在二級及以上的醫院進行裝機,二級醫院相對量會更大,三級醫院也會進行一些標杆醫院的建設,下半年會進行市場案例分享。對於裝機產出情況,首先公司會根據不同客户做相應的測算,確保投入產出,另外由於每一家客户進度不同,並非裝機後一兩個月就能夠有所呈現,通常會經過安裝、調試、啟用之後,逐步常態化,比如裝機運行後3-5個月試劑採購量會有一定增長,半年到一年逐漸有所放量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.